US retinal therapeutics market buoyant, says F&S

7 May 2012

Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering intensive ophthalmic research into vision-compromising co-morbidities, notes a new report from market research group Frost and Sullivan. The USA’s Centers for Disease Control and Prevention predicts that diabetic retinopathy will triple from 5.5 million in 2005 to 16.0 million in 2050.

As diabetes is the leading cause of blindness in working age people, improved treatments are urgently needed. The presence of novel biopharmaceuticals as well as advancements in formulation technology has boosted the outlook for the US retinal therapeutics market.

Analysis from Frost & Sullivan's US Retinal Therapeutics Market research estimates revenues in the age-related macular degeneration (AMD) segment of the market to reach $2.26 billion by 2016. Revenues in the diabetic macular edema (DME) segment are expected to reach $455.2 million by 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK